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We evaluated whether or not a patient’s area of primary residence is an independent risk factor for overall survival
(OS) after HLA-identical sibling or autologous hematopoietic stem cell transplantation (HSCT). This retrospec-
tive cohort study included patients who underwent autologous (n 5 1739) or HLA-identical sibling (n 5 267)
HSCT to treat a hematologic malignancy between 1983 and 2004 at the University of Nebraska Medical Center.
Primary area of residence, using the patient’s zip code, was categorized as either urban or rural (including iso-
lated, small rural, or large rural) according to the Rural Urban Commuting Area Codes (RUCA) classification sys-
tem. An association between area of primary residence and survival was examined using Cox proportional hazards
regression analysis while adjusting for patient-, disease-, and treatment-related variables. Patients from rural
areas who received autologous HSCT had a higher relative risk of death (relative risk 5 1.18; P 5 .016)
than urban patients who underwent the same procedure. Survival rates in patients from rural and urban locations
are as follows: 1 year, 73% vs 78% (P 5 .04); 5 year, 48% vs 54% (P 5 .012). We failed to detect a significant
difference in the risk of death according to primary area of residence in the HLA-identical sibling HSCT cohort,
although this may be from lack of statistical power. Our findings suggest that the primary location of a patient’s
residence may be an independent risk factor for survival after HSCT.
 2007 American Society for Blood and Marrow Transplantation
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Hematopoietic stem cell transplantation (HSCT)
is performed to treat various malignant and nonmalig-
nant hematologic disorders [1-5]. Although HSCT is
potentially curative and life-saving, it carries significant
medical risks. Most deaths after HSCT result from
disease recurrence; however, a significant number of
deaths are from preventable causes, such as infectious
complications, graft-versus-host disease (GVHD), and
multiorgan dysfunction.
Because of the complex nature of HSCT, not all
facilities are able to offer this treatment. Studies have
shown that improved survival outcome after HSCT is
associated with the number of transplantations that
a center performs and the expertise of the transplanta-
tionphysician [6-10]. As such, patientswhomay benefit1508from HSCT are often referred to larger hospitals.
Although patients stay in hospitals for a few weeks
during the peritransplantation period, follow-up care is
commonly brought back to the community or referring
physician at some point.
Most transplantation centers, at least in the United
States, are located in metropolitan areas and attract
a wide range of patients, including many from small
towns and rural areas. Physician shortages also force
many of these patients to travel great distances for
specific care [11,12]. Studies have shown that rural
residents must travel roughly twice the distance of their
urban counterparts to access advanced care [13,14].
Therefore, the geographical locationof both thepatient
and his or her community physician could differentially
affect follow-up and may be considered a risk factor
that may or may not affect clinical outcomes.
Survival Outcome after HSCT According to Area of Primary Residence 1509Consequently, this retrospective study was de-
signed to investigate whether disparities in survival
outcome among patients undergoing HSCT exist
according to patient’s place of residence. We hypoth-
esized that the patient’s area of primary residence
would be a significant factor associated with mortality
post-HSCT after adjusting for patient-, disease-, and
transplantation-related factors.
MATERIALS AND METHODS
Data Source
Data for the study were obtained from the Adult
Oncology Stem Cell Transplant Database at the
University of Nebraska Medical Center (UNMC) in
Omaha, Nebraska. This database contains patient-,
disease-, and treatment-related factors of all patients
who have undergone HSCT since UNMC started
performing HSCT in the early 1980s. A systematic
evaluation of outcomes after HSCT, including disease
recurrence or progression and survival status, is per-
formed annually at each patient’s anniversary date by
a trained clinical research associate. Data are also
reported to the Center for International Blood and
Marrow Transplant Registry. Each patient has signed
an informed consent allowing UNMC clinical person-
nel to contact the patient and his or her physician to
update clinical events of interest. Data are maintained
in a password-secured Oracle-based relational data-
base (ONCOBASE) that is also linked to the hospital’s
electronic medical records. This retrospective analysis
was approved byUNMC’s Institutional Review Board.
Patients
Because of the intrinsic differences in the compli-
cations and clinical outcomes of autologous and allo-
geneic HSCT, our study was designed to primarily
examine the effect of primary area of residence on
survival using prototype cohorts in which autologous
or allogeneic transplants are most commonly indi-
cated. Thus, the first cohort included 267 patients
who underwent HLA-identical sibling (allogeneic)
HSCT that was serologically matched for the 6 major
HLA alleles. Only patients with acute myelogen-
ous leukemia (AML), acute lymphoblastic leukemia
(ALL), or chronic myelogenous leukemia (CML)
who underwent transplantation between 1983 and
2004 were included. We did not have a sufficient
number of patients who received unrelated trans-
plants to allow us to conduct a separate analysis for
this cohort, which is also known to have a higher
risk of mortality compared with those receiving
HLA-identical sibling transplants. The second
cohort included 1739 patients who underwent auto-
logous transplantation for lymphoma (non-Hodgkin
[NHL] or Hodgkin) or multiple myeloma (MM) be-
tween 1983 and 2004.Variables Evaluated
The primary covariate evaluated in both of our
study cohorts was location of the patient’s primary
area of residence. A patient was classified as living in
either an urban area or a rural area according to his
or her residential zip code provided at the time of
transplantation. The rural category included the sub-
categories isolated rural towns, small rural towns,
and large rural towns. These classifications were based
on the Rural Urban Commuting Area Codes (RUCA)
created in part by the US Department of Agriculture’s
Economic Research Service [15]. The RUCA defines
patient location as urban ($ 50,000 residents), large
rural (10,000-49,000 residents), small rural (2500-
9999 residents), or isolated (\ 2499 residents) based
on the US Census Bureau’s definitions of urbanized
areas and urban clusters, which in turn rely on complex
criteria, including population density and population
work commuting patterns. The RUCA classification
system is based on the size of cities and towns and their
functional relationships asmeasured by work commut-
ing [15]. We also evaluated the distance traveled in
miles from a patient’s area of primary residence to
the transplantation center, as well as average household
income based on the patient’s zip code of residence as
obtained from Census 2000 data [16]. Categories for
continuous data were first created using quartile distri-
bution and further combined according to median
when no differences in outcomes were noted between
the first and second quartiles or between the third
and forth quartiles. The following additional covari-
ates were examined for their association with outcome:
patient age, sex, race, disease type, interval from diag-
nosis to transplantation, disease stage at transplanta-
tion, use of irradiation as part of treatment, type of
graft used, and the time period in which the patient
underwent transplantation. Covariates were catego-
rized according to conventional classifications used in
many previous studies, as given in Tables 1 and 3
[17-20].
Outcomes Evaluated
Two outcomes were evaluated. The primary
outcome was overall survival (OS), defined as death
from any cause, and the secondary outcome was pro-
gression-free survival (inverse of treatment failure), de-
fined as death or relapse and/or progression from
primary disease. All time intervals were computed
from the time of transplantation to the occurrence of
event or last contact, whichever was applicable.
Statistical Analysis
Univariate comparisons according to place of res-
idence were done using the c2 test for categorical
data andWilcoxon’s test for continuous data. The uni-
variate probability of survival was computed using the
1510 K. Rao et al.Kaplan-Meier estimate [21]. The multivariate analysis
was done using Cox proportional hazards regression
analysis to examine the association between primary
area of residence and the relative risk of death but
adjusting for other covariates [22]. In the multivariate
Table 1. Characteristics of patients undergoing autologous HCST
according to location of residence
Variable Urban Rural P value
n 1221 518
Median age, years (range) 43 (3-80) 46 (8-80) \ .001
# 20 76 (6) 25 (5) .003
20-40 428 (35) 147 (28)
41-59 579 (47) 261 (50)
$ 60 138 (11) 85 (16)
Male sex 725 (59) 310 (60) .86
Caucasians 1166 (96) 512 (99) \ .001
Diagnosis
Non-Hodgkin lymphoma 823 (67) 335 (65) \ .001
Hodgkin lymphoma 333 (27) 120 (23)
Multiple myeloma 65 (5) 63 (12)
Disease stage at
transplantation
First complete remission/
PIF sensitive
379 (31) 154 (30) \ .001
$ second complete
remission
133 (11) 47 (9)
Relapse 511 (42) 204 (39)
PIF 133 (11) 50 (10)
Multiple myeloma 65 (5) 63 (12)
Interval for diagnosis to
transplantation
# 1 year 448 (37) 218 (42) .03
. 1 year 773 (63) 300 (58)
Type of graft
Bone marrow 327 (27) 126 (24) .28
Peripheral blood 894 (73) 392 (76)
Use of TBI for conditioning
regimen
No 1048 (86) 445 (86) .97
Yes 173 (14) 73 (14)
Year of transplantation
1983-1989 211 (17) 93 (18) \ .001
1990-1997 572 (47) 194 (37)
1998-2004 438 (36) 231 (44)
Location according to
population size
Urban 1221 (100) —— NA
Isolated —— 182 (35)
Small rural area —— 124 (24)
Large rural area —— 212 (41)
Distance of residence to
transplant center, miles
# 50 207 (17) 18 (3) \ .001
51-99 74 (6) 61 (12)
100-500 307 (25) 335 (65)
. 500 633 (52) 104 (20)
Average annual income
# $40,000 115 (9) 153 (30) \ .001
$40,001-$49,999 241 (20) 310 (60)
$50,000-$65,000 424 (35) 41 (8)
. $65,000 398 (33) 9 (2)
Not available 43 (4) 5 (1)
TBI indicates total body irradiation.analyses, the main effect (area of primary residence),
dichotomized into urban versus rural, was forced in
all of the model building. We decided to combine
the 3 categories of rural areas after noting no statisti-
cally significant differences among the groups. One
by one, the covariates listed in both Tables 1 and 3
were examined for their effect on the outcome of inter-
est while retaining the main effect term. The assump-
tion of proportionality was tested in all of the model
building. Stepwise model building was used, and
only covariates found to have a P value # .05 were in-
cluded in themodel. All factors found to be statistically
significant were tested for first-order interaction (ie,
whether the effect of a patients’ place of primary
residence on survival varies according to the categories
of the other significant factor, eg, age strata or period
of transplantation). An a level # .01 was considered
to indicate a statistically significant interaction.
RESULTS
Table 1 shows that of the 1739 patients who under-
went autologous HSCT, 1221 (70%) lived in urban
areas and 518 (30%) lived in rural areas. Patients
coming from rural areas were likely to be older, with
Table 2. Multivariate analysis of risk of death in patients who underwent
autologous HCST according to location of residence, adjusting for
statistically significant covariates
Variable n
Relative risk of death
(95% confidence
interval) P value
Location of residence
Urban 1221 1.00
Rural 518 1.18 (1.03-1.36) .02
Other significant
factors
Age at
transplantation,
years
\.001*
# 20 101 1.00
20-40 575 0.89 (0.67-1.18) .41
41-59 840 1.03 (0.78-1.37) .83
$ 60 223 1.51 (1.08-2.11) .02
Disease stage at
transplantation
\ .001†
First complete
remission/
PIF-sensitive
533 1.00
$ second complete
remission
180 1.01 (0.78-1.31) .93
Relapse 715 1.27 (1.08-1.49) .003
PIF 183 1.60 (1.29-1.98) \ .001
Multiple myeloma 128 1.16 (0.80-1.69) .43
Year of transplantation \ .001‡
1983-1989 304 1.00
1990-1997 766 0.62 (0.52-0.72) \ .001
1998-2004 669 0.34 (0.28-0.42) \ .001
*3 degree of freedom test.
†4 degree of freedom test.
‡2 degree of freedom test.
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HSCT according to location of residence
Variable Urban Rural P value
N 172 95
Median age, years (range) 35 (\1-70) 35 (\1-70) .61
# 20 40 (23) 29 (30) .17
20-40 69 (40) 33 (35)
41-59 59 (34) 27 (28)
$ 60 4 (2) 6 (6)
Male sex 109 (63) 53 (56) .22
Caucasian 161 (94) 92 (97) .26
Diagnosis
Acute myelogenous
leukemia
79 (46) 46 (48) .93
Acute lymphoblastic
leukemia
36 (21) 19 (20)
Chronic myelogenous
leukemia
57 (33) 30 (32)
Disease stage at
transplantation
First complete
remission or chronic
phase
84 (49) 56 (59) .22
$ second complete
remission or chronic
phase, first accelerated
phase
32 (19) 17 (18)
Relapse, blastic phase,$
second accelerated
phase
56 (33) 22 (23)
Interval between diagnosis
and transplantation
# 1 year 123 (72) 72 (76) .45
. 1 year 49 (28) 23 (24)
Type of graft
Bone marrow 85 (49) 59 (62) .05
Peripheral blood 87 (51) 36 (38)
Use of TBI for
conditioning regimen
No 35 (20) 29 (30) .06
Yes 137 (80) 66 (70)
Year of transplantation
1983-1989 21 (12) 22 (23) .02
1990-1997 105 (61) 43 (45)
1998-2004 46 (27) 30 (32)
Location according to
population size
Urban 172 — NA
Isolated — 37 (39)
Small rural area — 17 (18)
Large rural area — 41 (43)
Distance between
residence and
transplantation center,
miles
# 50 59 (34) 5 (5) \ .001
51-99 20 (12) 14 (15)
100-500 46 (27) 67 (71)
. 500 47 (27) 9 (9)
Average annual income
# $40,000 22 (13) 28 (29) \ .001
$40,001-$49,999 26 (15) 60 (63)
$50,000-$65,000 63 (37) 5 (5)
. $65,000 56 (33) 1 (1)
Not available 5 (3) 1 (1)
TBI indicates total body irradiation.a median age of 46 years, compared with 43 years in
patients from urban areas. Patients from rural areas
were more likely to be Caucasians, more likely to un-
dergo autologous HSCT for MM, and more likely to
undergo HSCT within 1 year of diagnosis. As ex-
pected, patients from rural areas undergoing
autologous HSCT were more likely to live at least 100
miles away from the transplantation center and more
likely to have an average income\$50,000. In addi-
tion, a trend toward increasing numbers of HSCTs
in patients from rural areas can be seen.
Because primary area of residence is closely corre-
lated with distance from the transplantation center and
average income, we evaluated these 3 factors sepa-
rately. In univariate analysis, patients living in rural
areas had a greater risk of death (relative risk [RR] 5
1.17; 95% confidence interval [CI] 5 1.02-1.35;
P 5 .02) compared with those living in urban areas.
Patients living $ 100 miles from the transplantation
center also had a greater risk of death (RR 5 1.30;
95% CI 5 1.09-1.53; P 5 .003) compared with those
living \ 100 miles from the transplantation center.
Conversely, patients with an average annual income
of$ $50,000 or more had a lower risk of death (RR5
0.84; 95% CI 5 0.73-0.95; P 5 .007) compared with
those with an average annual income of \ $50,000.
However, in stepwise multivariate analysis, the inde-
pendent effects of distance from the transplantation
center and average income analyzed based on area of
residence and other prognostic covariates were no
longer statistically significant. Table 2 shows the results
of multivariate analysis evaluating the risk of death in
patients who underwent autologous transplantation
according to place of primary residence while adjusting
for statistically significant covariates. Compared with
patients from urban areas, those from rural areas had
an 18% higher risk of death (RR 5 1.18; 95% CI 5
1.03-1.36; P 5 .02). Other factors found to be associ-
ated with survival included age (patients over age 60
at higher risk of death), disease stage (patients not in
remission at transplantation at higher risk of death),
and year of transplantation (more recent transplanta-
tion recipients at lower risk of death).
Table 5 and Figure 1 show the OS probability and
plots of patients who underwent autologous HSCT
according to primary area of residence at 100 days, 1
year, and 5 years post-HSCT.
Table 3 compares characteristics of the 267
patients who underwent HLA-identical sibling HSCT
according to place of residence. Of these patients, 172
(64%) came from urban areas and 95 (36%) came from
rural areas. Surprisingly, patients undergoing HLA-
identical sibling HSCT had more similarities than
differences. A higher percentage of rural patients used
bone marrow as the graft tissue of choice compared
with their urban counterparts. Similar to the autolo-
gous cohort, patients from rural areas were more likely
1512 K. Rao et al.to live at least 100 miles away from the transplantation
center and more likely to have an average income
\$50,000. In addition, the number of transplantations
performed increased over time.
Our univariate analysis failed to demonstrate any
association between risk of death and primary area of
residence, distance from transplantation center, or
average annual income in patients who received HLA-
identical sibling transplants. This may result from the
small sample size, which provided inadequate statistical
power. Table 4 shows the results of multivariate analy-
sis for the risk of death in patients who received an
HLA-identical sibling transplant according to place of
Table 4. Multivariate analysis of risk of death in patients who underwent
HLA-identical sibling HSCT according to location of residence, adjusting
for statistically significant covariates
Variable n
Relative risk of death
(95% confidence
interval) P value
Location of residence
Urban 172 1.00
Rural 95 0.93 (0.67 – 1.29) .66
Other significant
factors
Age at
transplantation,
years
\ .001*
# 20 69 1.00
20-40 102 1.20 (0.79-1.84) .39
41-59 86 2.34 (1.53-3.58) \ .001
$ 60 10 4.06 (1.91-8.59) \ .001
Disease stage at
transplantation
\ .001†
First complete
remission or
chronic phase
140 1.00
$ second complete
remission or
chronic phase, first
accelerated phase
49 1.44 (0.94-2.19) .09
Relapse, blastic
phase, $ second
accelerated phase
78 2.81 (1.97-4.01) \ .001
*3 degree of freedom test.
†2 degree of freedom test.
Table 5. Probability of overall survival (95% confidence interval)
according to type of transplant and area of residence
Urban Rural P value
Autologous transplant
100-day overall survival 91 (89-92) 88 (85-90) .07
1-year overall survival 78 (75-80) 73 (69-77) .04
5-year overall survival 54 (52-57) 48 (43-52) .01
HLA-identical sibling transplant
100-day overall survival 76 (68-81) 81 (72-88) .29
1-year overall survival 56 (48-63) 58 (47-67) .74
5-year overall survival 42 (34-49) 42 (32-52) .99primary residence while adjusting for statistically sig-
nificant covariates. We failed to detect any statistically
significant differences in the risk of death according to
place of residence (RR 5 0.93; 95% CI 5 0.67-1.29;
P5 .66). As expected, the RR of death was dramatically
increased in older patients and in patients who under-
went transplantation at an advanced disease stage.
Table 5 and Figure 2 show the survival probability and
plots of the patients who underwent HLA-identical
sibling HSCT according to primary area of residence.
Our multivariate analyses of the risk of treatment
failure (inverse of progression-free survival; data not
shown) according to primary area of residence in the
autologous and HLA-identical sibling cohorts failed
to detect significant differences according to primary
area of residence in both cohorts. Table 6 shows the
causes of early (within 1 year) and late (after 1 year)
deaths in the patients who underwent autologous
transplantation. Approximately 60% of the primary
causes of death were from disease progression in
patients from either rural or urban areas.
DISCUSSION
Our study found a greater risk of death in patients
from rural areas, at least in the autologous HSCT
setting. Our data consistently showed that patients
Figure 1. Survival probability by area of residence for autologous
HSCT recipients.
Figure 2. Survival probability by area of residence forHLA-identical
sibling HSCT recipients.
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survival at 1 year and 5 years after undergoing autolo-
gous HSCT. But disparate survival rates were not
observed between urban and rural patients undergoing
HLA-identical sibling transplantation, possibly due to
a lack of statistical power.
Because there was no significant difference in treat-
ment failure according to primary area of residence in
the 2 types of transplants that we evaluated, the dispar-
ity in survival that we found may result from treatment
toxicity. Treatment-related complications that can
result in death may include graft failure, infection,
GVHD, and multiorgan dysfunction. These known
complications post-HSCT should be monitored for
closely according to the transplantation physician’s
recommendation [23]. Most of these clinical entities
are preventable or treatable when detected early; how-
ever, there remains a lack of consensus on the optimum
frequency of follow-up assessments. Commonly, allo-
geneic transplant recipients are seen more frequently
and are closelymonitored for complications (especially
during the first 100 days posttransplantation), whereas
autologous transplant recipients are discharged earlier
and return home to the care of referring community
oncologists or general internists. This has been the
practice at our center since the first HSCTs were per-
formed in the mid-1980s. The difference in the fol-
low-up care plan in autologous and allogeneic
transplant recipients serves as a plausible explanation
as to why survival in allogeneic transplant recipients
is similar regardless of location of residence. It also
accounts for the reduced survival in autologous
Table 6. Causes of death according to area of residence after autologous
transplantation
Urban Rural P value
Early (within 1 year) n 5 271 n 5 138 .22
Graft failure —— 1 (\1%)
Infection 19 (7%) 11 (8%)
IPN 5 (2%) 6 (4%)
ARDS 5 (2%) 3 (2%)
Relapse/progression 180 (66%) 95 (69%)
Organ failure 29 (11%) 14 (10%)
Hemorrhage 15 (6%) 1 (\1%)
Accidental death 2 (\1%) 2 (1%)
Others 7 (2%) 2 (1%)
Unknown 9 (3%) 3 (2%)
Late (after 1 year) n 5 379 n 5 152 .35
Infection 17 (4%) 3 (2%)
IPN —— 1 (\1%)
ARDS 4 (1%) 1 (\1%)
Relapse/progression 279 (74%) 109 (72%)
Organ failure 17 (4%) 10 (6%)
Secondary malignancy 34 (9%) 18 (12%)
Hemorrhage 5 (1%) 2 (1%)
Accidental death —— 1 (\1%)
Others 14 (4%) 5 (3%)
Unknown 9 (2%) 2 (1%)transplant recipients, in whom location of residence
then becomes a potential independent risk factor.
Previous studies have shown that rural patients had
to travel more than double the distance of their urban
counterparts for advanced care and were significantly
deterred by this prospect [13,14]. Their reluctance
increased exponentially as they had to make repeated
long trips for posttransplantation care that they may
have considered unnecessary. Consequently, instead
of returning to the transplantation physician, rural
patients discharged early after autologous transplanta-
tion may opt to go to a local primary care physician or
to avoid any follow-up care. Community general prac-
titioners generally have neither the experience nor the
resources to fully help these patients [12,24]; thus,
these patients may be monitored and treated by health
care personnel unfamiliar with the management of
posttransplantation complications, possibly leading
to misdiagnoses and untimely or inappropriate care.
Although our study found only a modest 5% decrease
in survival probability for rural patients, when applied
to larger populations, this rate may represent a signifi-
cant amount of preventable deaths. Although this
problem is more relevant in a state like Nebraska, in
which more than 2/3 of the counties qualify as under-
served rural areas, our finding may be generalizable to
other predominantly rural states and other states with
significant underserved populations [25].
There are also multiple alternative explanations to
our findings. Some believe that there are systematic
differences in the type of patients (in terms of, eg, dis-
ease stage, disease type, timing of transplantation) un-
dergoing HSCT coming from urban and rural areas.
In addition, although patients undergoing HSCT
represent a relatively select group of cancer patients
(good performance scores, no major organ dysfunc-
tion, adequate insurance coverage), this is likely to be
true for patients from both urban and rural areas.
It also should be noted that the retrospective
nature of our study presents some limitations. We
were not able to collect crucial information on the fre-
quency and nature of patient visits to follow-up care
providers posttransplantation, or on other comorbid
medical conditions developing posttransplantation
that usually lead patients to seek medical attention.
Although instructions given to patients regarding
posttransplantation hygiene practices, activities, food
intake, and other aspects do not vary according to place
of residence or transplant type, it would be useful to
evaluate whether there are any differences in how the
patient cohorts implement these instructions. It is
also of interest that distance from transplantation
center or average income was associated with survival
after autologous HSCT in the univariate models, but
the complex correlation of these factors with primary
area of residence in a retrospective study design
does not allow for a detailed exploration of these
1514 K. Rao et al.interactions. A carefully designed prospective study
should provide more insight into the causal relation-
ships among primary area of residence, income, and
distance traveled as they relate to survival and other
clinical prognostic factors. A prospective approach
also should help elucidate the role of health behavior
and medical utilization in differences in survival be-
tween patients from urban areas and those from rural
areas.
Our findings may have significant implications for
health policy makers, patients, and health care
providers. We established an independent temporal
relationship between the primary area of residence
(at least in the autologous HSCT setting) and patient
survival after HCST. Based on this, the transplanting
physician may need to consider the patient’s primary
location of residence as an independent risk factor
for survival. A comprehensive follow-up care plan
may need to be considered in the discussion of prog-
nostic factors, similar to how medical care providers
consider a patients’ age or disease stage in their deci-
sion of whether or not to perform transplantation.
Further studies should evaluate how follow-up care
of patients from rural areas are coordinated between
community referring physicians and transplantation
physicians to optimize outcomes. The medical com-
munity must define the frequency of follow-up care
visits using a prospective study design to gain insight
into inequities in health care provision.
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